FindTrial
Sign In

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

ANALYSIS OF THE EFFECTIVENESS OF A STAGED MANAGEMENT PROGRAM AIMED AT CONTROLLING BLOOD PRESSURE AND BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENTS USING EXCLUSIVELY THE RESOURCES AVAILABLE IN A PRIMARY CARE SETTING IN BRAZIL

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00935805
Enrollment
124
Registered
2009-07-09
Start date
2006-07-31
Completion date
2012-07-31
Last updated
2011-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Arterial Hypertension

Keywords

Diabetes Mellitus, Arterial Hypertension, Treatment, Primary Care

Brief summary

The aim of this study is to to analyze if it is possible to reach the goals of HbA1c \<7.0% and blood pressure \<= 130/80 mm Hg in a cohort of patients with type 2 diabetes attending a primary care unit, using ony those resources available at the unit, and provided by the Brazilian National Health System. It is an open label, observational study, with a duration of 4-6 years. Patients attending a primary care outpatient facility will be sequentially included in the study provided they give consent. They will be followed on a monthly basis by a team of physicians and nurses. Glucose, A1c, Blood PRessure will be the outcomes.

Interventions

DRUGMetformin

850 mg TID

DRUGGlybenclamide

10 mg BID

DRUGNPH insulin

Variable SC dose

DRUGHydrochlorothiazide

25 mg QD introduced as initial therapy for hypertension

DRUGPropranolol

40 mg BID

DRUGCaptopril

50 mg TID

DRUGAmlodipine

10 mg QD

Sponsors

Conselho Nacional de Desenvolvimento Científico e Tecnológico
CollaboratorOTHER_GOV
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil
CollaboratorOTHER
Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetes mellitus (WHO)

Exclusion criteria

* Terminal disease (renal, cancer, heart failure)

Design outcomes

Primary

MeasureTime frame
Glycated hemoglobin A1c3 months
Blood pressure1 month

Secondary

MeasureTime frame
24 hr blood glucose profileonce
Fasting blood glucose3 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026